Development and Evaluation of an adjuvanted protein pan-coronavirus vaccine
This project seeks to evaluate a potent adjuvant (3M052) with recombinant multimeric SARS-CoV-2 S-proteins in preclinical studies, toxicology studies for the lead candidates, and conduct a Phase 1 / 2 trial in healthy adult volunteers.
Countries
Faculty Involved